ClinicalTrials.gg
CompletedNCT02177890Updated Dec 2, 2015

Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy Volunteers

An interventional study of Transcutaneous vagal nerve stimulation and Sham vagal nerve stimulation in Visually Induced Motion Sickness in Healthy Volunteers, sponsored by Wingate Institute of Neurogastroenterology. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-02.

Sponsored by Wingate Institute of Neurogastroenterology · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Nausea is a common and distressing experience that often precedes vomiting. Amongst symptoms emanating from the gastrointestinal (GI) tract nausea can be considered somewhat unique, as on one hand it represents a normal, highly conserved, physiological response to an ingested toxin yet on the other it may indicate pathology. Nausea may also arise as a consequence of pharmaco- and chemotherapeutic interventions. Nausea negatively impacts on quality of life, adherence to treatment and is a cause for discontinuation of the development of novel compounds. Experimentally, nausea can be induced in humans using a visually induced motion stimulus. Previously we have developed a 10-minute motion video of the landscape rotating as seen from the perspective of a subject standing on Westminster Bridge, London. The tilted and rotating view visual display makes the subject perceive that they are spinning round and round on a spot tilted away from centre of gravity due to circular vection. This motion video induced nausea in approximately 50% of healthy participants and caused a reduction in cardiac vagal tone, a validated measure of the parasympathetic nervous system branch on the autonomic nervous system. We therefore are evaluating the role of external transcutaneous vagal nerve stimulation in visually induced motion sickness.

02

Conditions studied

  • Visually Induced Motion Sickness in Healthy Volunteers

Browse trials for

03

In context

Motion Sickness

50 studies on the registry are indexed under Motion Sickness; 9 are open to participants now.

This study's enrollment of 25 is below the median of 59 across 44 interventional studies indexed under Motion Sickness.

Browse Motion Sickness studies →

Lead sponsor

Wingate Institute of Neurogastroenterology is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects, aged 18-65, from staff, students and local population of Queen Mary, University of London.
  2. Inclusion will be determined on the basis of availability, with no prior selection bias included. They should be able to attend the Wingate Institute for at least 2 x 1 hour sessions.
  3. Subjects who score >15 on MSSQ (suggesting that they are sensitive to visually induced nausea).

Exclusion criteria

Exclusion Criteria:

  1. Subjects unable to provide .
  2. Subjects with any systemic disease or medications that may influence the autonomic nervous system (e.g. beta-agonists or Parkinson's disease).
  3. Subjects who score \<15 on MSSQ (suggesting that they are insensitive to visually induced nausea).
  4. Pregnant females to prevent any confounding effects on pregnancy related nausea.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Transcutaneous vagal nerve stimulation

    Active vagal nerve stimulation to the left auricular branch of the vagus nerve

    Device: Transcutaneous vagal nerve stimulation

  • Placebo comparator
    Sham vagal nerve stimulation

    Placebo vagal nerve stimulation - stimulator attached to the ear but rotated 180 degrees so that it is not stimulating the vagus nerve.

    Device: Sham vagal nerve stimulation

Interventions

  • DeviceTranscutaneous vagal nerve stimulation

    Also known as: NEMOS

  • DeviceSham vagal nerve stimulation
06

What researchers measure

Primary outcomes

  1. Reduction of the subjective sensation of nausea on a visual analogue scale

    Time frame: 10 minutes

Secondary outcomes

  1. Effect of transcutaneous vagal nerve stimulation on cardiac vagal tone

    Time frame: 10 minutes

  2. Tolerability of transcutaneous vagal nerve stimulation

    Time frame: 10 minutes

07

Study locations

1 site
  • Wingate Institute of Neurogastroenterology
    London, E1 @AJ, United Kingdom
08

References and documents

Publications

  • Farmer AD, Al Omran Y, Aziz Q, Andrews PL. The role of the parasympathetic nervous system in visually induced motion sickness: systematic review and meta-analysis. Exp Brain Res. 2014 Aug;232(8):2665-73. doi: 10.1007/s00221-014-3964-3. Epub 2014 May 4. PubMed 24792503 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jun 30, 2014
Start
Nov 2014
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
Dec 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02177890
Lead sponsor
Wingate Institute of Neurogastroenterology
Responsible party
Adam Farmer (Research fellow, Wingate Institute of Neurogastroenterology) — Principal investigator
First posted
Jun 30, 2014
Start date
Nov 2014
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Dec 2, 2015

Study contacts

Adam D Farmer, PhD MRCP
principal investigator · Wingate Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion